Skip to main content

Drug Interactions between eliglustat and rizatriptan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

rizatriptan eliglustat

Applies to: rizatriptan and eliglustat

Coadministration with rizatriptan may alter the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6. Rizatriptan has been shown to be a competitive inhibitor of CYP450 2D6 in vitro, but only at high, clinically irrelevant concentrations and a clinically significant inhibitory effect on CYP450 2D6 has not been demonstrated in clinical drug interaction studies. Based on these observations, rizatriptan may be administered with CYP450 2D6 substrates without the need for increased clinical monitoring

References (5)
  1. (2025) "Product Information. Symbravo (meloxicam-rizatriptan)." Axsome Therapeutics, Inc.
  2. (2020) "Product Information. Rizatriptan Benzoate (rizatriptan)." Exelan Pharmaceuticals Inc
  3. (2025) "Product Information. Rizatriptan (rizatriptan)." Organon Pharma (UK) Ltd
  4. (2018) "Product Information. Rizatriptan (rizatriptan)." Accel Pharma Inc
  5. (2024) "Product Information. Rizatriptan ODT (WGR) (rizatriptan)." GM Pharma International Pty Ltd

Drug and food interactions

Major

eliglustat food

Applies to: eliglustat

GENERALLY AVOID: Grapefruit juice may significantly increase the systemic exposure to eliglustat. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Because eliglustat is predicted to cause prolongation of the PR, QTc, and QRS cardiac intervals at substantially elevated plasma concentrations, consumption of grapefruit juice during treatment may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.

MANAGEMENT: Patients treated with eliglustat should avoid consumption of grapefruit and grapefruit juice.

References (1)
  1. (2014) "Product Information. Cerdelga (eliglustat)." Genzyme Corporation

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer